52 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Shandong University
MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design.
Tango Therapeutics
From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy.
Amgen Inc
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers.
Amgen Inc.
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion.
Tango Therapeutics
Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma.
Nanjing University of Chinese Medicine
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
GlaxoSmithKline
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Daiichi Sankyo Co., Ltd
An Adenosine Analogue Library Reveals Insights into Active Sites of Protein Arginine Methyltransferases and Enables the Discovery of a Selective PRMT4 Inhibitor.
Purdue University
Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity.
AstraZeneca
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers.
Tango Therapeutics
Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions.
China Pharmaceutical University
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
University of Salerno
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies.
Sun Yat-Sen University
Development of Macrocyclic PRMT5-Adaptor Protein Interaction Inhibitors.
Max Planck Institute of Molecular Physiology
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
Mirati Therapeutics
Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.
The Broad Institute of Mit and Harvard
A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode.
Janssen Pharmaceutica
Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders.
Icahn School Of Medicine At Mount Sinai
Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.
Epizyme
Pharmacophore-based screening of diamidine small molecule inhibitors for protein arginine methyltransferases.
University of Georgia
Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.
Shanghai Institute of Materia Medica
Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
Prelude Therapeutics
Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
University of Jinan
Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors.
Prelude Therapeutics
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Sun Yat-Sen University
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
Lilly Research Laboratories
Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
University of Jinan
Amino alcohol derivative, pharmaceutical composition and application thereof
Beijing Foreland Pharma
Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
The Johns Hopkins University
Substituted indoline derivatives as dengue viral replication inhibitors
Janssen Pharmaceuticals
Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
Exonate